Afibrinogenemia: congenital

[MIM 202 400]

Very rare (1 to 2 cases per million). Autosomal recessive transmission of a mutation of one of the 3 genes coding for fibrinogen: FGA, FGB or FGG at 4q31.3.

Congenital dysfibrinogenemia [MIM 616 004] is caused by the autosomal dominant transmission of other mutations in the same genes, and is  either asymptomatic (50 %) or associated with thrombotic risk (25 %) or both hemorrhagic and thrombotic risk (25 %).


The severity of clinical manifestations is variable depending on whether it is a - , hypofibrinogenemia or dysfibrinogenemia:


- bleeding at the fall of the umbilical cord in 85 % of cases

- intracranial hemorrhage

- frequent epistaxis, mucosal bleeding, post-traumatic hematomas

- hemarthroses

- sometimes no clinical symptoms.


Diagnosis: strongly abnormal clotting tests (APTT, INR) and dosage of fibrinogen.


 Anesthetic implications

administer fibrinogen (30-100 mg/kg) in order to obtain a blood level greater than 100 mg/100 ml: one usually needs 30 mg/kg to increase the fibrinogen concentration up to 100 mg/100 ml; if no fibrinogen is available, fresh frozen plasma may be used instead. Dynamic monitoring of coagulation (thromboelastography: ROTEM® ); it is useful to administer an antifibrinolytic (tranexamic acid: 25 mg/kg/6 h orally or 10mg/kg/6 h IV). Warning: 20 to 30 % of those patients have a paradoxal thrombophilia and must be closely monitored in the postoperative period (risk of thromboembolic event ?).


References : 


Updated May 2025